Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

(2022) Silke Gillessen et al.   EUROPEAN UROLOGY

A Prospective Trial Evaluating the Safety and Systemic Response From the Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer

(2021) Malcolm D. Mattes et al.   Clinical Lung Cancer

Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the ‘TOaSTT’ database

(2021) Stephanie G. C. Kroeze et al.   Radiation Oncology

Incidence, Risk Factors, and CT characteristics of Radiation Recall Pneumonitis induced by Immune Checkpoint Inhibitor in Lung Cancer

(2021) François Cousin et al.   RADIOTHERAPY AND ONCOLOGY

The NIPRO study: an observational, retrospective, multicenter study on the safety of the radiotherapy and immunotherapy combination for advanced-stage NSCLC: Immuno-Radiotherapy treatment in Advanced NSCLC

(2021) Marco Perna et al.   Clinical Lung Cancer

Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non–small-cell lung cancer: a propensity-matched retrospective study

(2021) Xia Wang et al.   BMC CANCER

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial

(2021) Nasser K Altorki et al.   LANCET ONCOLOGY

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients

(2021) Kuo-Hsuan Hsu et al.   OncoTargets and Therapy

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

(2021) Matthew J. Page et al.   International Journal of Surgery

Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature

(2021) Chao Liu et al.   BMC Urology

Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial

(2021) Hua Ye et al.   Frontiers in Oncology

A pilot study of everolimus and radiation for neuroendocrine liver metastases

(2021) Sten Myrehaug et al.   ENDOCRINE-RELATED CANCER

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial

(2021) Edmond M. Kwan et al.   EUROPEAN UROLOGY

Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study

(2021) Patrick Cheung et al.   EUROPEAN UROLOGY

A Phase I Trial of Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)

(2021) Christine M. Bestvina et al.   Journal of Thoracic Oncology

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

(2021) Xiaofei Zhu et al.   LANCET ONCOLOGY

Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial

(2021) Arjun Sahgal et al.   LANCET ONCOLOGY

Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

(2021) Jianjiao Ni et al.   Radiation Oncology

Stereotactic body radiotherapy and checkpoint inhibitor for locally recurrent unresectable nasopharyngeal carcinoma

(2021) Jia-Shing Wu et al.   BMJ Case Reports

Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

(2021) Cristina Masini et al.   EUROPEAN UROLOGY

Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis

(2021) Stephanie G. C. Kroeze et al.   Cancers

Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT)

(2021) Annie Xiao et al.   Practical Radiation Oncology

Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma

(2020) Changqing Xie et al.   CLINICAL CANCER RESEARCH

Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non–Small-Cell Lung Cancer

(2020) Gonzalo Pizarro et al.   Clinical Lung Cancer

Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis

(2020) Sibo Tian et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

(2020) Matthias Guckenberger et al.   LANCET ONCOLOGY

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials

(2020) Dawei Chen et al.   Journal for ImmunoTherapy of Cancer

Cyclin-dependent kinase 4/6 inhibitors combined with radiation therapy for patients with metastatic breast cancer

(2020) Ivica Ratosa et al.   Clinical Breast Cancer

The Effect of Systemic Hyperoxia and Hypoxia on Scotopic Thresholds in People with Early and Intermediate Age-related Macular Degeneration

(2020) Tamsin Callaghan et al.   CURRENT EYE RESEARCH

Stereotactic radiotherapy combined with immunotherapy against metastatic melanoma: Long term results of a phase I clinical trial

(2020) Gishan Ratnayake et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI

(2020) Oscar S.H. Chan et al.   LUNG CANCER

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib

(2020) Wenxiao Jia et al.   RADIOTHERAPY AND ONCOLOGY

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

(2020) Sean McBride et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

(2020) James Welsh et al.   Journal for ImmunoTherapy of Cancer

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review

(2020) Xiangrong Zhao et al.   Frontiers in Oncology

Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma

(2020) Stephanie G.C. Kroeze et al.   BJU INTERNATIONAL

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer

(2020) Eric J. Lehrer et al.   JAMA Oncology

Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study

(2020) Mónika Blake-Cerda et al.   LUNG CANCER

Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma

(2019) Nora Sundahl et al.   EUROPEAN UROLOGY

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

(2019) Alexandros Papachristofilou et al.   Journal for ImmunoTherapy of Cancer

Ipsilateral metastatic choroidal melanoma responds to systemic immunotherapy

(2019) Moanes Morkos et al.   EUROPEAN JOURNAL OF OPHTHALMOLOGY

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma

(2019) Nora Sundahl et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer

(2019) Charalampos S. Floudas et al.   Clinical Colorectal Cancer

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

(2019) Willemijn S. M. E. Theelen et al.   JAMA Oncology

Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity

(2019) Edy Ippolito et al.   BREAST

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade

(2019) Xiaoliang Liu et al.   Journal for ImmunoTherapy of Cancer

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors

(2019) Liru He et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

(2019) James W. Welsh et al.   Cancer Immunology Research

Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy

(2019) Chi-Leung Chiang et al.   Frontiers in Oncology

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

(2019) Kyriakos P. Papadopoulos et al.   CLINICAL CANCER RESEARCH

Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer

(2019) Julianna Higa et al.   Clinical Genitourinary Cancer

Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study

(2018) Matthias Guckenberger et al.   CANCER

Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation With Head and Neck Stereotactic Body Radiation Therapy

(2018) Brian J. Gebhardt et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma

(2018) Nora Sundahl et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer

(2018) Christian Britschgi et al.   Radiation Oncology

Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer

(2018) Icro Meattini et al.   BREAST

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

(2018) Amit Maity et al.   BRITISH JOURNAL OF CANCER

Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer

(2018) I. Desideri et al.   Clinical & Translational Oncology

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer

(2017) Michela Roberto et al.   MEDICINE

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center

(2017) Andrew Sharabi et al.   ONCOLOGIST

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial

(2017) Katrien De Wolf et al.   Radiation Oncology

Phase I trial of radiation therapy and sorafenib in unresectable liver metastases

(2017) Rebecca B. Goody et al.   RADIOTHERAPY AND ONCOLOGY

Lung cancer requires multidisciplinary treatment to improve patient survival: A case report

(2017) Aldo Pezzuto et al.   Oncology Letters

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

(2016) Chad Tang et al.   CLINICAL CANCER RESEARCH

Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

(2016) Anthony M. Brade et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Choroidal melanoma treated with stereotactic fractionated radiotherapy and prophylactic intravitreal bevacizumab: The Dunedin Hospital experience

(2016) Nur Azri Bin Haji Mohd Yasin et al.   Journal of Medical Imaging and Radiation Oncology

Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma

(2016) Jacob A. Miller et al.   JOURNAL OF NEUROSURGERY-SPINE

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

(2016) Daniel R Gomez et al.   LANCET ONCOLOGY

Toxicities Following Stereotactic Ablative Radiotherapy Treatment of Locally-Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma

(2016) Kimmen Quan et al.   SEMINARS IN RADIATION ONCOLOGY

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma

(2016) S. Theurich et al.   Cancer Immunology Research

A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck

(2015) John A. Vargo et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

(2014) Gregory N. Gan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer

(2014) Puneeth Iyengar et al.   JOURNAL OF CLINICAL ONCOLOGY

A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy

(2014) Susan M. Hiniker et al.   Translational Oncology

Increased Bowel Toxicity in Patients Treated With a Vascular Endothelial Growth Factor Inhibitor (VEGFI) After Stereotactic Body Radiation Therapy (SBRT)

(2013) Brandon M. Barney et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Ablation of a Site of Progression With Stereotactic Body Radiation Therapy Extends Sunitinib Treatment From 14 to 22 Months

(2013) Christopher Straka et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

(2013) Eric F. Lartigau et al.   RADIOTHERAPY AND ONCOLOGY

An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer

(2013) E. B. Golden et al.   Cancer Immunology Research

Gefitinib Combined With Stereotactic Radiosurgery in Previously Treated Patients With Advanced Non–Small Cell Lung Cancer

(2012) Zhen Wang et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study

(2012) Bénédicte Comet et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

(2012) Andrew J. Weickhardt et al.   Journal of Thoracic Oncology

Concurrent Cetuximab With Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2010) Dwight E. Heron et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS